# Q1FY24

**PERFORMANCE HIGHLIGHTS** 





## Q1 FY24 HIGHLIGHTS

- Collection growth of clinics in India was 4% vs Q1 FY23
- Collection declined by 9% in Middle East vs Q1 FY23
- In India, Collections from the Body business has witnessed a 5x growth vs Q1 FY23, Acne business grew by 9% and Product has grown by 13%
- In Middle East, Plastic Surgery business grew by 15% LFL vs Q1 FY23, Product grew by 6%
- Average Ticket Size grew in India in Q1 by 12% and in Middle East at 7% vs Q1 FY23
- Net promoter score in India was at 82 and in Middle East it was at 84 for Q1 FY24





Laser away your tanning and pigmentation woes with Insta Clarity Laser!





- OVERVIEW
- EXPANSION
- STRATEGIC PILLARS
- AWARDS
- COMPANY FINANCIALS





### **INDUSTRY OVERVIEW-INDIA**

Positive impact of Covid-19 in changing customer mindset towards wellness & aesthetics

Aesthetic Dermatology Market in India growing at a CAGR of 17%.



Growth is primarily driven by growing customer base across metros and non-metros, due to rapid urbanization



#### Aesthetic Dermatology poised for growth (FY 22 to FY 26):

 Health & wellness category is growing at a CAGR of 5.6% and the aesthetic dermatology sub-category is growing at a faster rate of 17%

## Young India consumers leading the spends on wellness and beauty

- 33% Millennials spent more than INR 4000 on wellness per month
- The wellness and beauty market is expected to thrive on India's younger working population with a median age of 28


## The future is bright with consumers seeking expert, tech driven, quick beauty solutions:

- New Technologies for Treatment: Low on pain, quicker recovery
- Changing Customer Needs: Rise of social media & easy availability of information on the internet, after Covid-19 has led
  - to a rise in consumer acceptance and affinity
- Utilization of AI Technology: Content based imaging for better diagnosis and treatment outcomes

## **INDUSTRY OVERVIEW- MIDDLE EAST**

Positive impact of Covid-19 in changing customer mindset towards wellness & aesthetics

GCC's aesthetic dermatology market is expected to register strong growth at CAGR of 29.7%.



The rise of the aesthetic dermatology market in the region can be attributed to several factors, including high household income, medical advancements, strong media influence, increased awareness, and rapid growth in medical tourism.

## Key factors that are augmenting the growth within aesthetic dermatology segment (FY 22 to FY 26):

- High GDP per capita: Growing economies have led to high GDP per capita of USD 20,000 in GCC countries
- Population influx: Post-Expo 2020, the UAE has witnessed a rise in immigrants, primarily from South Asian countries.
   Meanwhile, KSA harbors a substantial expat community, comprising 13 million individuals from diverse nations, representing roughly one-third of the country's population.

#### The changing landscape - Regional trends

- Cultural liberalization: Less stigma against aesthetic alterations
- Evolving audience: In GCC region, around 30% of aesthetic dermatology procedures are now performed on men, compared with about 15% globally.
- Advancement in aesthetic dermatology treatments: Noninvasive aesthetic treatments have gained popularity in the GCC region over past few years.



## **KAYA OVERVIEW**

90+ CLINICS

31+ CITIES

4 COUNTRIES

Skin, Hair & Body SERVICES

60+ PRODUCTS

Over 100K
KAYA SMILES
MEMBERS

85%+ WOMEN WORKFORCE





## **KAYA'S GLOBAL PRESENCE**

## **INDIA**

16 Indian States

**26** Cities

74 Clinics

## **MIDDLE EAST**


**03** Countries

**09** Cities

23 Clinics



- OVERVIEW
- EXPANSION
- STRATEGIC PILLARS
- AWARDS
- COMPANY FINANCIALS





## **BRAND REFRESH**

#### Kaya's New Growth Engine

- Kaya started a brand refresh campaign to improve customer experience by investing on infrastructure and technology at Jetalpur (Baroda) and Adyar (Chennai) in Q1 FY24
- Jetalpur has a fantastic 5 star rating on Google My Business and Adyar is high at 4.5
- Jetalpur witnessed a 13% growth in collection and Adyar grew by 41%
- Kaya has invested in renovating 6 clinics Pan India in Q1
- Additionally, Kaya has invested in upgrading technology in clinic with 46 new machines launched in Q1 FY24









## **PRODUCT**

USP - Dermat Backed | 70+ Strong Portfolio

#### **Kaya India Clinics:**

- Kaya Clinic product collection witnessed 13% growth vs Q1 FY23
- Lighter & Brighter products are up by 30% vs Q1 FY23, contributing to 17% of the current portfolio

#### **Kaya Middle East Clinics:**

 Product collection witnessed 6% growth (at constant currency) vs Q1 FY23, driven by Acne, Pigmentation and Sun Protection





## STRATEGIC PILLARS

KAYA SMILES (Loyalty Program)

**SERVICES** 

**PRODUCTS** 

**INNOVATION** 











## **KAYA SMILES**

Loyalty Program

#### **Kaya India Clinics:**

- Contributing to 92% of Kaya Clinics collection
- The average ticket size of Platinum and Gold Elite customers was 63% higher than other tiers

#### **Kaya Middle East Clinics:**

- Contributing to more than 87% of Q1 FY24 collection
- The average ticket size of Platinum and Gold Elite customers was 2.7X higher than other tiers







The laser increases the skin's susceptibility to photodamage.

Thus, it is crucial to apply sunscreen after the procedure.

## **SERVICES**

Skin | Hair | Body 100+ Dermats | 90+ Clinics

#### **Kaya India Clinics:**

- Services collection witnessed a 2.3% growth vs Q1FY23
- The leading category Body stays strong with a 5X collection growth vs Q1FY23
- Acne service grew by 9% vs Q1FY23

#### **Kaya Middle East Clinics:**

- Services collection witnessed a 10% decline vs Q1 FY23
- Plastic Surgery grew by 15% vs Q1 FY23








The laser light only targets the dark pigment in the hair follicle and does not affect the surrounding skin.





## INNOVATION

Contributed to 8% of Kaya Group Clinic Business











# INNOVATION Al Powered CX

- Launch of AI enabled D2C site that aids in Self Diagnosis with product recommendations
- The AI tool is being used successfully by Kaya's expert Dermats in clinics for consultative services selling
- The usage of the tool by Dermats has led to a 600 BPS higher customer conversion; adding to 26% incremental revenue in Acne and Brightening & Pigmentation segment





## INNOVATION

New Product Development

#### **INDIA**

We launched a body range for acne beyond face: Acne Soothe and Pure Cleanse

First time ever launch of post laser soothing gel: Gentle Restoring Body Gel to complement our laser hair reduction business









## INNOVATION

New Product Line: Nutraceuticals

#### **INDIA**

Strengthened Kaya India's product portfolio with the launch of nutraceutical in powder and capsule formats

Nutraceuticals contributed to 23% of Q1 FY24 product business


Glutathione contributed to 50% of the nutraceutical business







## INNOVATION NEW SERVICES DEVELOPMENT

Contributed To 10% Of The Kaya India Clinic Business










## INNOVATION NEW SERVICES DEVELOPMENT

Contributed To 7% Of The Kaya Middle East Business

# **ANTI-AGEING** Facetem, Innovyal, PB Serum, Artfiller







Hydrafacial, Profacial, Royal Facial



Dutasteride Meso hair therapy





## **AWARDS & RECOGNITIONS**



e4m Health and Wellness Marketing
Awards 2023

Campaign Name : Beautiful is You Subcategory : Best Brand Identity







## **AWARDS & RECOGNITIONS**



At the 5<sup>th</sup> Edition CHRO Vision & Innovation Summit and Awards **`Our Active Consultation Skills'** program for CMs was recognized for **Excellence in Learning & Development at Kaya India** 




Kaya India has been honored with an award from L&D Confex 2023 for innovative approach in soft skills and L&D interventions.



Kaya India won an award for **HR Excellence in Employee Engagement** at the 5<sup>th</sup> Edition CHRO Vision & Innovation Summit for fostering belongingness and inclusivity among members.



- OVERVIEW
- EXPANSION
- STRATEGIC PILLARS
- AWARDS
- COMPANY FINANCIALS






## Q1 FY24 FINANCIALS







#### **KEY PERFORMANCE INDICATORS - CLINIC BUSINESS**

#### <u>India</u>













#### Middle East











Kaya Classification | Public


#### **KAYA CONSOLIDATED - HIGHLIGHTS**

- <u>Collection</u> grew by 0.3% over Q1 FY23
- Net Revenue grew by 14% over Q1 FY23
- <u>EBITDA</u> of INR 12.9 crs in Q1 FY24 as compared to INR (5.6) crs in Q1 FY23
- <u>EBITDA</u> in Q1 FY23 includes one-time impact of INR 10.8 crs primarily due to PF liability of INR 8.8 crs and Rates & taxes of INR 2.0 crs
- <u>PAT</u> bei at INR (10.4) crs, as compared to INR (25.6) crs in Q1 FY23













#### **KAYA STANDALONE - HIGHLIGHTS**

- <u>\*Clinic Collection</u> grew by 4% over Q1 FY23
- Net Revenue grew by 17% over Q1 FY23
- Clinic Net Revenue grew by 20% over Q1 FY23
- <u>EBITDA</u> of INR 9.2 crs in Q1 FY24 as compared to INR (7.0) crs in Q1 FY23
- <u>EBITDA</u> in Q1 FY23 includes one-time impact of INR 10.8 crs primarily due to PF liability of INR 8.8 crs and Rates & taxes of INR 2.0 crs
- <u>PAT</u> bei of INR (4.5) crs as compared to INR (18.7) crs in Q1 FY23











#### **KAYA MIDDLE EAST - HIGHLIGHTS**

- <u>Collection</u> declined by 3% in Q1 FY24 over Q1 FY23 (at constant currency declined by 9%).
- Net Revenue grew by 11% in Q1 FY24 over Q1 FY23
- <u>Service Revenue</u> grew by 11% in Q1 FY24 over Q1 FY23
- Product Revenue grew by 13% in Q1 FY24 over Q1 FY23
- Average Ticket size (at constant currency) grew by 7% in Q1 FY24 over Q1 FY23





#### **FINANCIAL HIGHLIGHTS: Q1 FY24**

Particulars (INR crs)	Standalone			Consolidated		
	Q1 FY24	Q1 FY23	Gr %	Q1 FY24	Q1 FY23	Gr %
Collection*	54.7	52.8	4%	111.1	110.8	0.3%
Net Revenue	49.7	42.6	17%	105.7	92.8	14%
EBITDA	9.2	(7.0)		12.9	(5.6)	
% to NR	19%	-16%		12%	-6%	
Operating Margin	1.4	(12.9)		(2.4)	(19.1)	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
% to NR	3%	-30%		-2%	-21%	7
PAT bei	(4.5)	(18.7)		(10.4)	(25.6)	
% to NR	-9%	-44%		-10%	-28%	
PAT aei**	(4.5)	(18.8)		(9.3)	(23.5)	
% to NR	-9%	-44%		-9%	-25%	

\*Collection includes only clinic collections

Net Revenue grew by 14% over Q1 FY23

EBITDA margin is 12% of NR as against -6% of NR in Q1 FY23

EBITDA Margin in Q1 FY23 includes one-time impact of INR 10.8 crs primarily due to PF liability of INR 8.8 crs and Rates & taxes of INR 2.0 crs

Operating Margin is at -2% of NR as against -21% of NR in Q1 FY23

\*\* PAT aei is PAT after other comprehensive income and noncontrolling interest

